Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Next Previous
Trial Profile

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Triple negative breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 06 Jun 2023 Results of exploratory analysis assessing the role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in ovarian cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 19 Apr 2023 Results of preliminary analysis(n=49 of biopsy cohort: n=25 and non-biopsy cohort: n=24) assessing biomarker analysis of prexasertib in BRCA wild-type platinum-resistant recurrent, high-grade serous ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 11 Aug 2022 Status changed from completed to discontinued (Eli Lilly prematurely terminated the study)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top